# Olema Pharmaceuticals, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Olema Pharmaceuticals, Inc.). ## Overview Olema Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies for breast cancer and related endocrine-driven cancers. Its pipeline centers on palazestrant and OP-3136, with development and future commercialization intended in the United States and other key markets, either independently or with partners. ## Products & services • Palazestrant, a next-generation ER-targeted breast cancer candidate • OP-3136, a KAT6 inhibitor in clinical development • Clinical-stage oncology drug development programs • Partnered development and commercialization collaborations • Third-party manufacturing and clinical supply management - **Palazestrant** (55%) — Lead endocrine therapy candidate being developed for ER+ breast cancer in multiple settings. - **OP-3136** (25%) — KAT6 inhibitor program being evaluated for combination use in breast cancer. - **Clinical development services** (15%) — Preclinical and clinical development activities supporting the pipeline. - **Collaboration and partnering** (5%) — Research and development collaborations intended to expand development and commercialization reach. - Palazestrant, a next-generation ER-targeted breast cancer candidate - OP-3136, a KAT6 inhibitor in clinical development - Clinical-stage oncology drug development programs - Partnered development and commercialization collaborations - Third-party manufacturing and clinical supply management ## Customers Olema does not sell commercial products today; its near-term counterparties are clinical investigators, trial sites, contract manufacturers, licensors, and collaboration partners. If approved, its end customers would be oncologists, hospitals, and cancer treatment centers prescribing therapies for patients with ER+ breast cancer and other endocrine-driven cancers. - **Clinical trial sites and investigators** (primary) — They run studies of palazestrant and OP-3136 and enable patient enrollment and data generation. - **Pharmaceutical collaboration partners** (primary) — Partners such as Novartis and Pfizer collaborate on development and may support future commercialization. - **Contract manufacturers and service providers** (primary) — CMOs provide drug substance, drug product, labeling, and distribution for clinical supply. - **Future oncology prescribers and treatment centers** (emerging) — If approved, oncologists and cancer centers would prescribe the therapies to patients with ER+ breast cancer. - Clinical trial sites enrolling breast cancer patients - Oncologists and cancer centers as future prescribers - Pharmaceutical partners for development and commercialization - CMOs supplying drug substance, drug product, and packaging - Licensors and research collaborators supporting pipeline work ## Geography Olema is headquartered in the United States and conducts its development activities through a global clinical and manufacturing network. The company expects to commercialize in key markets either alone or with partners, and its risk profile is shaped by international regulatory, supply-chain, and intellectual-property exposure. - Headquartered in the United States - Clinical development and partnering extend beyond the U.S. - Commercialization is intended in key global markets - Third-party manufacturing may involve international supply chains - Foreign regulatory and IP regimes affect future expansion ## Strategy Olema’s strategy is to advance palazestrant in multiple ER+ breast cancer indications and to develop OP-3136 as a complementary oncology program. The company also seeks collaborations that can accelerate development timelines, broaden capabilities, and improve eventual commercialization reach. - **Advance palazestrant across ER+ breast cancer settings** (short-term) — The lead asset is the main value driver and the foundation of the pipeline. - **Develop OP-3136 in combination regimens** (medium-term) — A second clinical program can broaden the pipeline and create combination opportunities. - **Build partnering and commercialization optionality** (medium-term) — External partners can add development speed, market access, and commercial infrastructure. - **Secure scalable manufacturing readiness** (medium-term) — Commercial approval would require reliable API, fill-finish, and packaging capacity. - Advance palazestrant through multiple breast cancer indications - Develop OP-3136 in clinical combination settings - Use collaborations to speed development and expand capabilities - Prepare for future commercialization in key markets - Qualify additional manufacturers before approval ## Risks Olema faces the core risks of a clinical-stage biotech: no approved products, dependence on successful trials and regulatory outcomes, and ongoing need for external capital. Its pipeline also depends on third-party manufacturers, intellectual-property protection, and the ability to compete against much larger oncology companies with established development and commercial capabilities. - **No products approved for commercial sale** [critical] — The company has no product revenue and must prove clinical and regulatory success before commercialization. - **Need for additional capital** [high] — Development-stage operations require ongoing funding for trials, manufacturing, and public-company costs. - **Clinical development and regulatory risk** [high] — Trial design, efficacy, safety, and approval decisions determine whether assets can advance. - **Third-party manufacturing dependence** [medium] — The company relies on CMOs for clinical and future commercial supply, creating execution and quality risk. - **Competitive intensity in oncology** [high] — Large pharma and biotech peers may develop similar or superior therapies faster. - **Intellectual property protection** [high] — Value depends on protecting proprietary compounds and related uses across jurisdictions. - No approved products, so future success depends on clinical and regulatory outcomes - Substantial capital needs could force delays or program reductions - Clinical trial failure or safety issues could impair the pipeline - Dependence on CMOs creates supply and quality-control risk - Large oncology competitors may reach approval or market first ## Accounting The main accounting judgments are typical of a development-stage biotech: accrued research and development expenses, stock-based compensation, and estimates tied to clinical and manufacturing obligations. Because the company has no product revenue, reported results are driven by expense timing, milestone or collaboration accounting if any, and valuation of financing-related items rather than sales recognition. - **Accrued research and development expenses** — Can shift operating expenses between quarters - **Stock-based compensation** — Affects reported losses and diluted share count - **Collaboration and milestone accounting** — Can create volatility in reported revenue or other income if applicable - **Clinical and manufacturing commitments** — Affects liabilities and cash requirement disclosures - Accrued R&D expenses depend on estimating trial and CMO invoices - Stock-based compensation affects operating expense and equity dilution - No product revenue means results are driven by expense timing - Milestone or collaboration accounting may affect period-to-period comparability - Public-company financing costs and warrant/option items can affect equity and cash flow --- *Last updated: 2026-04-29T04:43:42.559020+00:00*